Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias

Clinical Cancer Research

Volumn 9, Issue 17, 2003, Pages 6335-6342

  Gandhi, Varsha ^a   Kantarjian, Hagop ^a   Faderl, Stefan ^a   Bonate, Peter ^b   Du, Min ^a   Ayres, Mary ^a   Rios, Mary Beth ^a   Keating, Michael J ^a   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ilex Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CLOFARABINE 5' TRIPHOSPHATE; DEOXYADENOSINE TRIPHOSPHATE; NUCLEOSIDE ANALOG; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MAXIMUM TOLERATED DOSE; MODELS, CHEMICAL; NEOPLASM CIRCULATING CELLS; OLIGONUCLEOTIDES; TIME FACTORS;

EID: 0346963139     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Schiffer, C. A. Acute myeloid leukemia in adults: where do we go from here? Cancer Chemother. Pharmacol. 48 (Suppl.): S45-S52, 2001.
2. Plunkett, W., and Gandhi, V. Purine and pyrimidine nucleoside analogs. In: G. Giaccone, R. Schilsky, and P. Sondel (eds.), Cancer Chemotherapy and Biological Response Modifiers, Annual, Vol. 19, pp. 21-45. Amsterdam: Elsevier Science Publishers, B. V., 2001.
3. Gandhi, V., Plunkett, W., Du, M., Ayres, M., and Estey, E. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a Phase I trial in relapsed acute myelogenous leukemia. J. Clin. Oncol., 20: 665-673, 2002.
4. Rizzeri D. A., Bass, A, J., Rosner, G. L., Gockerman, J. P., DeCastro, C. M., Petros, W. P., Adams, D. J., Laughlin, M. J., Davis. P., Foster, T., et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J. Clin. Oncol., 20: 674-679, 2002.
5. Silverman, L. R., Demakos, E. P., Bercedis, L., Kornblith, A. B., Holland, J. C., Odchimar-Reissig, R., Stone, R. M., Nelson, D., Powell, B. L., DeCastro, C. M., et al. A randomized controlled trial of azacytidine in patients with myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol., 20: 2429-2440, 2002.
6. Wijermans, P, Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., Ferrant, A. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol., 18: 956-962, 2000.
7. Giles, F., Faderl, S., Thomas, D., Cortes, J. E., Garcia-Manero, G., Douer, D., Levine, A. M., Koller, C. A., Jeha, S. S., O'Brien, S. M., et al. Randomized Phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J. Clin. Oncol., 21: 1050-1056, 2003.
8. Keating, M. J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L. E., Freireich, E. J., Estey, E., and Kantarjian, H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92: 1165-1171, 1998.
9. Piro, L. D., Carrera, C. J., Carson, D. A., and Beutler, E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med., 322: 1117-1121, 1990.
10. Montgomery, J. A., Shortnacy-Fowler, A. T., Clayton, S. D., Riordan, J. M., and Secrist, J. A., III. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J. Med. Chem., 35: 397-401, 1992.
11. Parker, W. B., Allan, P. W., Hassan, A. E., Secrist, J. A., III 111, Sorscher, E, J., and Waud, W. R. Antitumor activity of 2-fluoro-2′ -deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther., 10: 23-29, 2003.
12. Carson, D. A., Wasson, D. B., Esparza, L. M., Carrera, C. J., Kipps, T. J., and Cottam, H. B. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′deoxyadenosine. Proc. Natl. Acad. Sci. USA, 89: 2970-2974, 1992.
13. Parker, W. B., Shaddix, S. C., Rose, L. M., Shewach, D. S., Hertel, L. W., Secrist, J. A., III, Montgomery, J. A., and Bennett, L. L., Jr. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β -D-ribofuranosyl)adenine 2-chloro-9-(2-deoxy-2, 2-difluoro-β -D-ribofuranosyl)adenine in CEM cells. Mol. Pharmacol., 55: 515-520, 1999.
14. Parker, W. B., Shaddix, S. C., Chang, C. H., White, E. L., Rose L. M., Brockman, R. W., Shortnacy, A. T., Montgomery, J. A. Secrist, J., A., III, and Bennett, L. L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res., 51: 2386-2394, 1991.
15. Parker, W. B., Bapat, A. R., Shen, J. X., Townsend, A. J., and Cheng, Y. C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol., 34: 485-491, 1988.
16. Xie, C., and Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fiuoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res., 55: 2847-2852, 1995.
17. Xie, K. C., and Plunkett, W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β -D-arabinofuranosyl)adenine. Cancer Res., 56: 3030-3037, 1996.
18. Kantarjian, H., Gandhi, V., Kozuch, P., Faderl, S., Giles, F., Cortes, J., O'Brien, S., Ibrahim, N., Khuri, F., Du, M., et al. Phase I clinical and pharmacology study of clofarabine (CI-F-ara-A; 2 chloro-2′ -fluorodeoxy-9-β-D-arabinofuranosyladenine) in patients with solid and hematologic cancers. J. Clin. Oncol., 21: 1167-1173, 2003.
19. Plunkett, W., Hug, V., Keating, M., and Chubb, S., Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β -D-arabinofuranosylcytosine therapy. Cancer Res., 40: 588-591, 1980.
20. Gandhi, V., Chen, W., Ayres, M., Rhie, J. C., Madden, T. L., and Newman, R. A. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats, Cancer Chemother. Pharmacol., 50: 85-94, 2002.
21. Rodriguez, C. O., Jr., Plunkett, W., Paff, M. T., Du, M., Nowak, B., Ramakrishna, P., Keating, M. J., and Gandhi, V. A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J. Chromatography B, 745: 421-430, 2000.
22. Sherman, P. A., and Fyfe, F. A. Enzymatic assay for deoxynucleotide triphosphates using synthetic oligonucleotides as template primer. Anal. Biochem., 180: 222-229, 1989.
23. Plunkett, W., Liliemark, J. O., Adams, T. M., Nowak, B., Estey, E., Kantarjian, H., and Keating, M. J. Saturation of 1-β -D-arabinofuranosylcytosine 5′triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res., 47: 3005-3011, 1987.
24. Grunewald, R., Abbruzzese, J. L., Tarassoff, P., and Plunkett, W. Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a Phase I trial of gemcitabine. Cancer Chemother. Pharm., 27: 258-262, 1991.
25. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., Raber, M. N., et al. A Phase I clinical, plasma, and cellular pharmacology study of 2′,2′-difluorodeoxycytidine. J. Clin. Oncol., 9: 491-498, 1991.
26. Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarassoff, P., and Plunkett, W. Gemcitabine (2′,2′-difluorodeoxycytidine) in leukemia: a Phase I clinical, plasma and cellular pharmacology study. J. Clin. Oncol., 10: 406-413, 1992.
27. Patel, S. R., Gandhi, V., Jenkins, J., Papadopolous, N., Burgess, M. A., Plager, C., Plunkett, W., and Benjamin, R. S. Phase II clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol., 19: 3483-3489, 2001.
28. Estey, E. H., Plunkett, W., Gandhi, V., Rios, M. B., Kantarjian, H., and Keating, M. J. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk. Lymphoma, 9: 343-350, 1993.
29. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol., 11: 116-124, 1993.
30. Tempero, M., Plunkett, W., Ruiz van Hapern, V., Hainswoth, J., Hochster, H., Lenzi, R., and Abbruzzese, J. A randomized Phase II comparison of dose intense gemcitabine: 30-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol., 21: 3402-3408, 2003.
31. Hughes, T. L., Hahn, T. M., Reynolds, K. K., and Shewach, D. S. Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate. Biochemistry, 36: 7540-7547, 1997.
32. Yamauchi, T., Nowak, B., Keating, M. J., and Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res., 7: 3580-3589, 2001.
33. Albertioni, F., Lindemalm, S., Reichelova, V., Pettersson, B., Eriksson, S., Juliusson, G., and Liliemark, J. O. Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin. Cancer Res., 4: 653-658, 1998.
34. Danhauser, L., Plunkett, W., Keating, M. J., and Cabanillas, F. 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-phosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol., 18: 132-145, 1986.
35. Kemena, A., Gandhi, V, Shewach, D. S., Keating, M. J., and Plunkett, W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother. Pharmacol., 31: 193-199, 1992.
36. Gandhi, V, Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez, C. O., Jr., Ramakrishna, P., Rosner, G. L, Hodge, J. P., and Keating, M. J. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J. Clin. Oncol., 19: 2142-2152, 2001.
37. Gandhi, V., Plunkett, W., Rodriguez, C. O., Kisor, D. F., Mitchell, B. S., Kurtzberg, J., and Keating, M. J, Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J. Clin. Oncol., 16: 3607-3615, 1998.
38. Plunkett, W., Iacoboni, S., Estey, E., Danhauser, L., Liliemark, J. O., and Keating, M. J. Pharmacologically-directed ara-C therapy for refractory leukemia. Semin. Oncology, 12 (Suppl. 3): 20-30, 1985.
39. Kantarjian, H. M., Estey, E., Plunkett, W., Keating, M. J., Walters, R. S., Iacoboni, S. McCredie, K. B., and Freireich, E. J. Phase I-II and cellular pharmacology study of high dose cytosine arabinoside in refractory leukemia. Am. J. Med., 81: 387-394, 1986.
40. Kantarjian, H., Gandhi, V., Cortes J., Verstovsek, S., Du, M, Garcia-Manero, G., et al. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemias. Blood, 102: 2379-2386, 2003.
41. Jeha, S. Gandhi, V., Chan, K. W., McDonald, L., Ramirez, I., Madden, R., Rytting, M. Brandt, M., Keating, M., Plunkett, W., et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia (electronically published ahead of print). Blood, in press, 2004.